Autonomic Nervous System Drugs Practice Questions

Q: Which is the complete neuromuscular blocking agent with the shortest duration of action?

Mivacurium. **Explanation:** The duration of action of non-depolarizing neuromuscular blocking agents (NMBAs) is primarily determined by their metabolism and elimination pathways. **Why Mivacurium is correct:** Mivacurium is a benzylisoquinoline derivative and is the **shortest-acting** non-depolarizing NMBA. Its brief duration (approximately 12–18 minutes) is due to its rapid hydrolysis by **plasma cholinesterase** (pseudocholinesterase), similar to the mechanism of succinylcholine. This makes it unique among non-depolarizing agents, which typically have longer durations. **Analysis of Incorrect Options:** * **Rocuronium:** An intermediate-acting steroid-based NMBA. It has the fastest *onset* of action among non-depolarizers (useful for rapid sequence intubation) but a duration of 30–40 minutes. * **Pipecuronium:** A long-acting NMBA with a duration exceeding 60–90 minutes. It is rarely used in modern practice due to its prolonged effect. * **Pancuronium:** A long-acting steroid-based NMBA. It is known for causing vagolytic effects (tachycardia) and has a duration of 60–120 minutes. **High-Yield Clinical Pearls for NEET-PG:** * **Shortest Acting (Overall):** Succinylcholine (Depolarizing agent; ~5–10 mins). * **Shortest Acting (Non-depolarizing):** Mivacurium. * **Fastest Onset (Non-depolarizing):** Rocuronium. * **Hoffman Elimination:** Atracurium and Cisatracurium undergo spontaneous degradation (independent of renal/hepatic function), making them drugs of choice in **liver or kidney failure**. * **Mivacurium Caution:** Its action is prolonged in patients with **pseudocholinesterase deficiency**. It can also cause histamine release if injected rapidly.

Q: Which muscarinic receptor subtype is predominantly found on the endothelium of blood vessels?

M3. ### Explanation **Correct Option: C (M3)** Muscarinic receptors are G-protein coupled receptors (GPCRs). The **M3 receptor** is the predominant subtype found on the **vascular endothelium**. The mechanism is a high-yield concept: although blood vessels lack direct parasympathetic innervation, they express "non-innervated" M3 receptors. When a muscarinic agonist (like Acetylcholine) binds to these M3 receptors, it activates the **Gq pathway**, increasing intracellular calcium. This stimulates the enzyme **Nitric Oxide Synthase (eNOS)** to produce **Nitric Oxide (NO)**. NO diffuses into the underlying vascular smooth muscle, increases cGMP, and causes **vasodilation**. *Note:* If the endothelium is damaged, acetylcholine acts directly on M3 receptors on the smooth muscle itself, causing vasoconstriction. **Why other options are incorrect:** * **A. M1:** These are primarily "Neural" receptors found in the CNS, autonomic ganglia, and gastric parietal cells (increasing HCl secretion). * **B. M2:** These are "Cardiac" receptors found in the SA node, AV node, and atria. They are coupled with Gi proteins and cause a decrease in heart rate and contractility. * **D. Nm:** These are Nicotinic receptors found at the **Neuromuscular Junction (NMJ)**. They are ligand-gated ion channels, not GPCRs, and are responsible for skeletal muscle contraction. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Receptors:** **M1, M2, M3** follow the rule **"Q-I-Q"** (Gq, Gi, Gq). * **M3 Locations:** "Wet and Constrict" — Exocrine glands (sweat, salivation), Eye (miosis/accommodation), GI/Bladder (contraction), and Bronchi (bronchoconstriction). * **Vascular Paradox:** Acetylcholine causes vasodilation *in vivo* (via NO from M3), but can cause vasoconstriction in isolated strips of blood vessels where the endothelium is removed.

Q: Which of the following inhibits the rate-limiting step in the synthesis of epinephrine?

Metyrosine. **Explanation:** The synthesis of catecholamines (Dopamine, Norepinephrine, and Epinephrine) follows a specific enzymatic pathway: **Tyrosine → L-Dopa → Dopamine → Norepinephrine → Epinephrine.** 1. **Why Metyrosine is correct:** The conversion of **Tyrosine to L-Dopa** by the enzyme **Tyrosine Hydroxylase** is the **rate-limiting step** in catecholamine synthesis. **Metyrosine (α-methyltyrosine)** competitively inhibits this enzyme, thereby decreasing the production of all subsequent catecholamines. It is clinically used in the preoperative management of **Pheochromocytoma**. 2. **Why other options are incorrect:** * **Guanethidine & Bretylium:** These are adrenergic neuron blockers. They do not inhibit synthesis; instead, they interfere with the **release** of norepinephrine from the presynaptic nerve terminals. * **Reserpine:** This drug inhibits the **Vesicular Monoamine Transporter (VMAT)**. It prevents the storage of neurotransmitters by blocking their transport into synaptic vesicles, leading to their degradation by MAO in the cytoplasm. **High-Yield NEET-PG Pearls:** * **Rate-limiting enzyme:** Tyrosine Hydroxylase (Inhibited by Metyrosine). * **Final step in Epinephrine synthesis:** Occurs in the adrenal medulla where Norepinephrine is converted to Epinephrine by **PNMT** (Phenylethanolamine N-methyltransferase). * **VMAT Inhibition:** Reserpine causes "pharmacological sympathectomy" and can lead to severe depression as a side effect. * **Uptake-1 Inhibition:** Cocaine and Tricyclic Antidepressants (TCAs) inhibit the reuptake of Norepinephrine into the neuron.

Q: Which of the following is an adverse effect of beta agonists?

Hypokalemia. The correct answer is **Hypokalemia**. **Mechanism of Action:** Beta-2 ($eta_2$) agonists (such as Salbutamol or Terbutaline) stimulate the $eta_2$ receptors located on the cell membranes of skeletal muscles. This stimulation activates the **Na⁺/K⁺-ATPase pump**, which drives potassium ions from the extracellular fluid into the intracellular compartment. This shift results in a decrease in serum potassium levels (Hypokalemia) [1]. This physiological effect is why nebulized salbutamol is used as an emergency treatment for hyperkalemia. **Analysis of Incorrect Options:** * **A. Hypoglycemia:** Incorrect. $\beta_2$ agonists actually cause **Hyperglycemia**. They stimulate glycogenolysis (breakdown of glycogen to glucose) in the liver and skeletal muscle, and promote glucagon release. * **B. Hypomagnesemia & C. Hypophosphatemia:** While high doses of $\beta_2$ agonists can occasionally cause minor shifts in other electrolytes, they are not classic or high-yield adverse effects compared to the profound effect on potassium. **NEET-PG High-Yield Pearls:** 1. **Metabolic Effects of $\beta_2$ Agonists:** Remember the "Hypo-Hyper" rule: **Hypo**kalemia, but **Hyper**glycemia and **Hyper**lactatemia. 2. **Cardiovascular Effects:** $\beta_2$ agonists can cause reflex tachycardia and tremors (due to direct action on skeletal muscle $\beta_2$ receptors). 3. **Clinical Application:** In patients with severe asthma or COPD receiving frequent nebulization, always monitor serum potassium to prevent cardiac arrhythmias. 4. **Uterine Effect:** $\beta_2$ agonists (e.g., Ritodrine, Isoxsuprine) act as tocolytics by relaxing the uterine smooth muscle.

Q: What is a Phase I blocker?

Depolarization blockade. **Explanation:** Neuromuscular blocking agents are classified into two main categories based on their mechanism of action at the nicotinic acetylcholine receptors (nAChR) of the motor endplate: **Depolarizing** and **Non-depolarizing** agents. **Why Option A is Correct:** Succinylcholine (Suxamethonium) is the only clinically used depolarizing muscle relaxant. It acts as an agonist at the nAChR, causing prolonged stimulation. This leads to an initial depolarization of the motor endplate (clinically seen as **fasciculations**), followed by a persistent state where the membrane cannot repolarize to receive further impulses. This initial mechanism is termed a **Phase I Blockade**. Key characteristics include the absence of "fade" on Train-of-Four (TOF) stimulation and the absence of post-tetanic facilitation. **Why Other Options are Incorrect:** * **Option B (Desensitization blockade):** This is synonymous with a **Phase II Blockade**. It occurs after prolonged exposure or high doses of Succinylcholine. The membrane eventually repolarizes but becomes "desensitized" and unresponsive to acetylcholine, behaving like a non-depolarizing block (showing "fade" on TOF). * **Option C & D:** These are incorrect as Phase I is specifically defined by the initial depolarization event. **NEET-PG High-Yield Pearls:** * **Metabolism:** Succinylcholine is rapidly metabolized by **Pseudocholinesterase** (Plasma cholinesterase). * **Side Effects:** Hyperkalemia (avoid in burns/trauma), bradycardia (especially in children), and it is a potent trigger for **Malignant Hyperthermia**. * **Anticholinesterases:** Giving Neostigmine during a Phase I block will **prolong** the paralysis rather than reverse it, as it increases the concentration of acetylcholine at the junction.

Q: Which is a short-acting non-depolarizing neuromuscular blocker?

Mivacurium. **Explanation:** Neuromuscular blockers (NMBs) are classified based on their mechanism of action (Depolarizing vs. Non-depolarizing) and their duration of action (Short, Intermediate, or Long-acting). **1. Why Mivacurium is correct:** Mivacurium is a benzylisoquinolinium derivative and is the only **short-acting non-depolarizing** NMB currently used. Its short duration (approx. 15–20 minutes) is due to its rapid metabolism by **plasma cholinesterase** (pseudocholinesterase), similar to succinylcholine. **2. Analysis of Incorrect Options:** * **Pancuronium:** This is a **long-acting** non-depolarizing NMB (duration >60 minutes). It is known for its vagolytic effect, which can cause tachycardia. * **Succinylcholine:** While it is short-acting, it is a **depolarizing** NMB. It acts as an agonist at nicotinic receptors, causing persistent depolarization. * **Rapacurium:** Although it was a rapid-onset, short-acting non-depolarizing agent, it was **withdrawn** from the market worldwide due to the high risk of severe bronchospasm. **3. High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** Most non-depolarizing drugs are metabolized by the liver or excreted by kidneys. Exceptions are **Atracurium and Cisatracurium**, which undergo **Hofmann elimination** (spontaneous degradation in plasma), making them safe in liver/kidney failure. * **Mivacurium Caution:** Since it is metabolized by plasma cholinesterase, its action is prolonged in patients with **pseudocholinesterase deficiency**. * **Histamine Release:** Mivacurium can cause histamine release, potentially leading to hypotension and flushing. * **Reversal:** Non-depolarizing blocks are reversed using Neostigmine (acetylcholinesterase inhibitor).

Question 1

Which of the following drugs will decrease heart rate in a patient with a normal heart rate but will have little effect on heart rate in a cardiac transplant recipient?

Accepted Answer

Phenylephrine

Answer

Adrenaline

Answer

Noradrenaline

Answer

Isoproterenol

Question 2

Which is the complete neuromuscular blocking agent with the shortest duration of action?

Accepted Answer

Mivacurium

Answer

Rocuronium

Answer

Pipecuronium

Answer

Pancuronium

Question 3

Which of the following is true about dobutamine?

Accepted Answer

Half-life is about 2 minutes

Answer

Selective beta-1 receptor agonist

Answer

Increases ventricular filling pressure

Answer

Dopamine receptor agonist

Question 4

A 28-year-old woman has been treated with several autonomic drugs for about a month. Which of the following signs would distinguish between an overdose of a muscarinic blocker and a ganglionic blocker?

Accepted Answer

Postural hypotension

Answer

Blurred vision

Answer

Dry mouth, constipation

Answer

Mydriasis

Question 5

Which muscarinic receptor subtype is predominantly found on the endothelium of blood vessels?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

Nm

Question 6

A 15-year-old boy needs to go for a long distance in a bus. Which of the following drugs would be useful for him to prevent motion sickness?

Accepted Answer

Promethazine

Answer

Desloratadine

Answer

Cetirizine

Answer

Diphenhydramine

Question 7

Which of the following inhibits the rate-limiting step in the synthesis of epinephrine?

Accepted Answer

Metyrosine

Answer

Guanithidine

Answer

Bretylium

Answer

Reserpine

Question 8

Which of the following is an adverse effect of beta agonists?

Accepted Answer

Hypokalemia

Answer

Hypoglycemia

Answer

Hypomagnesemia

Answer

Hypophosphatemia

Question 9

What is a Phase I blocker?

Accepted Answer

Depolarization blockade

Answer

Desensitization blockade

Answer

Both

Answer

Neither

Question 10

Which is a short-acting non-depolarizing neuromuscular blocker?

Accepted Answer

Mivacurium

Answer

Pancuronium

Answer

Succinylcholine

Answer

Rapacurium

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?